Additive Anti-inflammatory Action for Critically Ill Patients With Cardiovascular Surgery (Xuebijing) IV

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Nanjing Medical University
Updated on 19 August 2021
cardiopulmonary bypass
cardiovascular surgery


XueBiJing, a Chinese herbal derived therapeutic, has been approved to treat severe infections (sepsis) in critically ill patients (China Food and Drug Administration; Beijing, China, Number Z20040033). Cardiopulmonary bypass (CPB) will produce large amounts of inflammatory mediators and oxygen free radicals, which causes the lipid peroxidation damage and mononuclear cell migration, thus aggravating organ inflammation and damage. Therefore, exploring new methods to prevent and alleviate organ injury caused by CPB is an important topi in clinical practice. However, little knowledge is regarding the effect of Xuebijing injection on CPB-related organ injury. To answer these questions, the authors conducted this randomized trial to compare XueBiJing with placebo in critically ill patients with cardiovascular surgery.

Condition Critical Illness, critically ill, cardiovascular disorders, Coronary Artery Disease, VALVULAR HEART DISEASE, Cardiac Ischemia, Coronary heart disease, Myocardial Ischemia, cardiovascular diseases, cardiovascular disease (cvd), Aortic Dissection, Aneurysm, Congenital Heart Disease, Heart Valve Disease, Cardiovascular Disease, cardiovascular system diseases
Treatment Normal saline, Xuebijing Injection
Clinical Study IdentifierNCT04993794
SponsorNanjing Medical University
Last Modified on19 August 2021


Yes No Not Sure

Inclusion Criteria

Patients who received cardiovascular surgery fulfilled three or more of the following
Agree to participate in the study and sign the informed consent
Pao2/Fio2 ratio less than or equal to 250mm Hg
Respiratory rate greater than or equal to 30 breaths/min
Blood urea nitrogen greater than 20mg/dL
WBC count < 4,000 cells/mm3 or >15 000 cells/mm3 not due to other causes
Core temperature < 36C or >38.5C
Receiving treatment with vasopressors at therapeutic doses after adequate fluid resuscitation
radiographic findings of new pulmonary infiltrate(s)

Exclusion Criteria

Pregnant and lactating women
Allergic to Xuebijing and its ingredients, or have severe allergies
Mental illness with poor compliance
Severe primary disease (active pulmonary tuberculosis, asthma, cystic pulmonary fibrosis, pulmonary sarcoidosis, pulmonary interstitial fibrosis, unresectable tumors, blood diseases, Alzheimer s disease, or HIV)
Participation in other clinical trials in the previous 30 days
Patients who are unsuitable for participation or unable to participate in this trial according to the judgment of the investigators (existing risk of potential medical disputes, and severe heart failure limiting the amount of liquid intake)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note